Partnerships for Outsourcing eBook
Read the article:
Preparing for the Future: Expanding Capacity and Facilitating Multi-modalities
Read the eBook:
CDMOs need to consistently demonstrate agility as demand increases for newly developed therapeutic modalities.
Maks_Lab - Stock.adobe.com
The COVID-19 pandemic highlighted the potential of an array of modalities within the biopharmaceutical industry. In particular, the success of messenger RNA (mRNA)-based COVID-19 vaccines has encouraged biopharmaceutical companies to explore and utilize these technologies for other diseases and look to rapidly expand their capacity and capabilities in response to an upsurge in demand.
Read the article:
Preparing for the Future: Expanding Capacity and Facilitating Multi-modalities
Read the eBook:
At the end of 2019, the combined market capitalization of the five publicly listed companies focusing on mRNA platforms was $15 billion, and as of August 2021, that value of capitalization reached more than $300 billion (1). This significant boost in market valuation reflects the optimism that mRNA technology can deliver much more and go beyond the current prophylactic COVID-19 vaccines.
Read this article in BioPharm International's Partnerships for Outsourcing eBook.
James Park is executive vice-president and managing director of the Global Sales Center at Samsung Biologics.
BioPharm International
eBook: Partnerships for Outsourcing
May 2022
Pages: 24–27
When referring to this article, please cite it as J. Park, “Preparing for the Future: Expanding Capacity and Facilitating Multi-modalities,” BioPharm International Partnerships for Outsourcing eBook (May 2022).
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.